The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

Pfizer’s respiratory syncytial virus (RSV) vaccine has been approved by the European Commission (EC) to prevent ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...

The European Commission (EC) has issued a decision amending the marketing authorization for Abrysvo, US pharma giant Pfizer’s ...

Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...

Contracting a non-COVID lower respiratory tract infection raises the risk of death 2 to 7 times over the next month to a year ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Pfizer shares are trading lower Wednesday after a Wall Street Journal report revealed that U.S. prosecutors are investigating ...

Australian medicines regulator, the Therapeutic Goods Administration (TGA), has granted approval for mRESVIA (mRNA-1345), an ...